{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:23:12Z","timestamp":1788988992285,"version":"build-2803163510"},"reference-count":7,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,3,3]],"date-time":"2022-03-03T00:00:00Z","timestamp":1646265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Posterior reversible encephalopathy syndrome (PRES) is a disorder of reversible subcortical vasogenic brain oedema in patients with acute neurological symptoms. Drug\u2010induced PRES has been described with the usage of drugs that target receptors regulating vascular permeability or altering immune response. Lenvatinib is a receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors implicated in cancer progression in addition to their normal cellular functions. The oedema associated with PRES is a consequence of disruption of cerebral blood flow autoregulation. Herein, we present a case of a 77\u2010year\u2010old lady who was on treatment with Lenvatinib for metastatic thyroid cancer who subsequently developed PRES. Her clinical and radiological findings improved after discontinuing Lenvatinib and the patient was switched to a different drug and remains asymptomatic on the same. This is the first such report of atypical findings of PRES in a patient on Lenvatinib therapy. Recognition of this entity is crucial for timely withdrawal of the drug and prevent further morbidity and mortality.<\/jats:p>","DOI":"10.1002\/cnr2.1605","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T06:58:01Z","timestamp":1646377081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer\u2014A case report"],"prefix":"10.1002","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6606-6537","authenticated-orcid":false,"given":"Mahajan","family":"Abhishek","sequence":"first","affiliation":[{"name":"Department of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashtekar","family":"Renuka","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agarwal","family":"Ujjwal","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Choudhari","family":"Amit","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Imaging Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patil","family":"Vijay","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noronha","family":"Vanita","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4214-5799","authenticated-orcid":false,"given":"Menon","family":"Nandini","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabash","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Tata Memorial Hospital, Tata Memorial Centre, Homi Bhabha National Institute  Mumbai Maharashtra India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,3,3]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(15)00111-8"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.05.006"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A0549"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2012.00152"},{"key":"e_1_2_9_6_1","first-page":"129","article-title":"Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib","volume":"8","author":"Stjepanovic N","year":"2014","journal-title":"Biol Theory"},{"key":"e_1_2_9_7_1","unstructured":"LENVIMA Guidebook;Lenvatinib management information for doctors provided by Eisai2015http:\/\/www.eisai.co.jp"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2015.4059"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1605","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.1605","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1605","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T12:21:13Z","timestamp":1692793273000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,3]]},"references-count":7,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1002\/cnr2.1605"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1605","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,3]]},"assertion":[{"value":"2021-08-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-09","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1605"}}